Stock Track | Arvinas Plummets 6.44% as Q2 Revenue Misses Estimates and CEO Announces Retirement

Stock Track

Aug 06

Shares of Arvinas Holding Company LLC (ARVN) plummeted 6.44% in pre-market trading on Wednesday following the release of its second-quarter financial results and a major leadership change announcement.

The clinical-stage biotechnology company reported Q2 revenue of $22.4 million, falling significantly short of the consensus estimate of $34.42 million. This represents a substantial drop from the previous year, primarily due to the completion of its agreement with Novartis. Despite the revenue miss, Arvinas posted a smaller-than-expected loss per share of $0.84, compared to the consensus estimate of $0.89.

Adding to investor concerns, Arvinas announced that its CEO, President, and Chairperson, John Houston, Ph.D., plans to retire from his executive roles. While Houston will remain as the Chairperson of the Board of Directors, the company has initiated a search for a new CEO. This leadership transition appears to have further unsettled investors, contributing to the stock's sharp decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1196869570"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196869570\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196869570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196869570","market":"nz","top_or_hot":-1,"title":"Stock Track | Arvinas Plummets 6.44% as Q2 Revenue Misses Estimates and CEO Announces Retirement","media":"Stock Track","content":"<p>Shares of Arvinas Holding Company LLC (ARVN) plummeted 6.44% in pre-market trading on Wednesday following the release of its second-quarter financial results and a major leadership change announcement.</p>\n\n<p>The clinical-stage biotechnology company reported Q2 revenue of $22.4 million, falling significantly short of the consensus estimate of $34.42 million. This represents a substantial drop from the previous year, primarily due to the completion of its agreement with Novartis. Despite the revenue miss, Arvinas posted a smaller-than-expected loss per share of $0.84, compared to the consensus estimate of $0.89.</p>\n\n<p>Adding to investor concerns, Arvinas announced that its CEO, President, and Chairperson, John Houston, Ph.D., plans to retire from his executive roles. While Houston will remain as the Chairperson of the Board of Directors, the company has initiated a search for a new CEO. This leadership transition appears to have further unsettled investors, contributing to the stock's sharp decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arvinas Plummets 6.44% as Q2 Revenue Misses Estimates and CEO Announces Retirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arvinas Plummets 6.44% as Q2 Revenue Misses Estimates and CEO Announces Retirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-06 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Arvinas Holding Company LLC (ARVN) plummeted 6.44% in pre-market trading on Wednesday following the release of its second-quarter financial results and a major leadership change announcement.</p>\n\n<p>The clinical-stage biotechnology company reported Q2 revenue of $22.4 million, falling significantly short of the consensus estimate of $34.42 million. This represents a substantial drop from the previous year, primarily due to the completion of its agreement with Novartis. Despite the revenue miss, Arvinas posted a smaller-than-expected loss per share of $0.84, compared to the consensus estimate of $0.89.</p>\n\n<p>Adding to investor concerns, Arvinas announced that its CEO, President, and Chairperson, John Houston, Ph.D., plans to retire from his executive roles. While Houston will remain as the Chairperson of the Board of Directors, the company has initiated a search for a new CEO. This leadership transition appears to have further unsettled investors, contributing to the stock's sharp decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARVN","symbol_name":"Arvinas Holding Company LLC","start_time":0,"source_url":"","article_id":"1196869570","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196869570","pubTimestamp":1754487647,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Arvinas Holding Company LLC (ARVN) plummeted 6.44% in pre-market trading on Wednesday following the release of its second-quarter financial results and a major leadership change...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARVN":"Arvinas Holding Company LLC"},"translate_title":"个股追踪|Q2营收不及预期CEO宣布退休Arvinas暴跌6.44%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":1},"content_text":"Shares of Arvinas Holding Company LLC (ARVN) plummeted 6.44% in pre-market trading on Wednesday following the release of its second-quarter financial results and a major leadership change announcement.\nThe clinical-stage biotechnology company reported Q2 revenue of $22.4 million, falling significantly short of the consensus estimate of $34.42 million. This represents a substantial drop from the previous year, primarily due to the completion of its agreement with Novartis. Despite the revenue miss, Arvinas posted a smaller-than-expected loss per share of $0.84, compared to the consensus estimate of $0.89.\nAdding to investor concerns, Arvinas announced that its CEO, President, and Chairperson, John Houston, Ph.D., plans to retire from his executive roles. While Houston will remain as the Chairperson of the Board of Directors, the company has initiated a search for a new CEO. This leadership transition appears to have further unsettled investors, contributing to the stock's sharp decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}